A High Prevalence of Cardiopulmonary Worms Detected in the Iberian Wolf (Canis lupus): A Threat for Wild and Domestic Canids.

Cardiopulmonary nematodes are highly pathogenic parasites affecting domestic and wild canids. As the result of conservation programs, the Iberian wolf (Canis lupus signatus) population has recently expanded, and its distribution range covers lands from where it had long disappeared. However, the exact epidemiological role of the wolf in the life cycle of zoonotic parasites causing diseases transmissible to pets and/or humans is largely unknown. This study sought to determine the diversity of cardiopulmonary nematode parasite species that affect wolves inhabiting northwestern areas of the Iberian Peninsula, and to estimate their prevalence and the relationship between these parasites and several epidemiological variables. For this purpose, we examined the cardiopulmonary systems of 57 wolves from Galicia (from the provinces A Coruña n = 15, Lugo n = 21, Ourense n =15 and Pontevedra n = 6) using techniques of dissection and cup sedimentation. Collected worms were then identified under a light microscope according to their morphological features. Three species of nematodes were detected: Angiostrongylus vasorum (the "French-heartworm"), Crenosoma vulpis and Eucoleus aerophilus, the latter being of zoonotic interest. The prevalence was 24.5% (14/57; 95% CI 13.3-35.6%) overall, 19.3% for A. vasorum (11/57; 95% CI 8.8-29.2%), 7% for C. vulpis (4/57; 95% CI 0.4-13.6%) and 3.5% for E. aerophilus (2/57; CI -1.1-9.1%). A significant relationship (p = 0.002) was found between age and the presence of C. vulpis, which was only found in juvenile animals. Furthermore, a higher prevalence of A. vasorum and/or C. vulpis was observed in wolves with a lower body condition score (40% and 20%, respectively), though the difference was not significant (p = 0.221 and p = 0.444, respectively). Our findings indicate a high "French-heartworm" and lungworm burden in the wolf population of northern Spain, and they identify a need for studies designed to elucidate the epidemiological role played by the Iberian wolf and to identify possible risks for veterinary and public health.

Clinical experience with linezolid for the treatment of neurosurgical infections

Introducción: Evaluar el uso clínico de linezolid en el tratamiento de las infecciones neuroquirúrgicas. Métodos: Estudio retrospectivo observacional de una cohorte de pacientes hospitalizados que recibieron linezolid para tratamiento de infecciones neuroquirúrgicas con cultivo positivo, desde Julio de 2004 a febrero de 2009 en un hospital terciario español. Resultados: En el estudio se incluyeron 17 pacientes. Las principales comorbilidades fueron una o más de las siguientes: hemorragia subaracnoidea o intraventricular (n= 8), tumor sólido neurológico (n= 7), corticoides (n= 9) e hidrocefalia ( n= 6). Ocho pacientes fueron sometidos a craneotomía y 14 tenían un drenaje ventricular externo (EVD) como factor predisponente de infección. La meningitis fue la infección más común (11; 64,7%), seguida de ventriculitis (4; 23,5%) y absceso cerebral (2; 11,8%). El principal agente causal fue Staphylococcus spp coagulasa negativa (13; 76,5%). Linezolid fue usado como tratamiento incicial en 8 episodios, tras fracaso en 6 y por otras razones en 3. La vía oral fue usada en 9 (52,9%) episodios, de forma inicial en 2 casos. La duración media del tratamiento fue de 26,5 días (rango 15-58). No se observaron efectos adversos. Dieciseís pacientes (94,1%) fueron considerados curados. Hubo una recurrencia. La estancia media en el hospital fue de 45,6 (rango 15-112) días y la duración media del seguimiento fue de 7,2 (rango 0,4-32) meses. No hubo muertes relacionadas con los episodios activos. Coclusiones: Linezolid fue principalmente indicado en las infecciones postquirúrgicas asociadas a EVD por Staphylococcus spp coagulasa negativa. Fue inicialmente usado en la mayoría de los casos. Una alta tasa de curación clínica fue observada y no se detectaron efectos adversos. Más de la mitad de los pacientes se beneficiaron de las ventajas de la vía oral(AU)

Objectives: We sought to evaluate the clinical use of linezolid for the treatment of neurosurgical infections. Methods: Retrospective observational study of a cohort of hospitalized patients who received linezolid for a culture-positive neurosurgical infection from July 2004 to February 2009 in a tertiary hospital in Spain. Results: Seventeen patients were included in the study. Main comorbidities among these patients included one or more of the following: subarachnoidal or intraventricular hemorrhage (n=8), solid neurological cancer (n=7), corticosteroids (n=9) and hydrocephalus (n=6). Eight patients underwent a craniotomy and fourteen patients had an external ventricular drainage (EVD) as predisposing factors for infection. Meningitis was the most common infection (11; 64.7%), followed by ventriculitis (4; 23.5%) and brain abscesses (2; 11.8%). The main causative organisms were coagulase-negative Staphylococcus spp. (13; 76.5%). Linezolid was used as the initial therapy in 8 episodes, after therapy failure in 6 and for other reasons in 3. The oral route was used in 9 (52.9%) episodes; linezolid was initiated orally in 2 cases. The mean duration of treatment was 26.5 days (range 15-58). No adverse events were reported. Sixteen (94.1%) patients were considered cured. There was one recurrence. The mean length of hospital stay was 45.6 (range 15-112) days and the mean duration of follow- up was 7.2 (range 0.4-32) months. No related deaths occurred during active episodes. Conclusions: Linezolid was mainly indicated in post-neurosurgical EVD-associated infections due to coagulase-negative Staphylococcus spp. It was used as initial therapy in most cases. A high rate of clinical cure was observed and no related adverse events were reported. More than half of the patients were benefited by the advantages of the oral route of administration(AU)